OKUR Issues Second Quarter 2025 Earnings Press Release (Exhibit 99.1)

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025. The company attached that press release as Exhibit 99.1 to this Current Report and described the release as reporting second-quarter financial results and providing a business update.

The report states that the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to the liabilities of being "filed" under the Exchange Act. The filing also shows that OnKure's Class A common stock trades as OKUR on The Nasdaq Stock Market and that the company is identified as an emerging growth company.

Insights

Securities Analyst

TL;DR: Routine earnings release furnished; no financial details provided in the filing to assess impact.

The company furnished a press release reporting second-quarter results for the period ended June 30, 2025, and attached it as Exhibit 99.1. The 8-K explicitly states the release is furnished, not filed, limiting legal exposure. The form confirms Nasdaq listing (OKUR) and emerging growth company status. Because the filing contains no revenue, expense, cash flow, or guidance figures, there is no basis in this document alone to judge financial performance or valuation impact.

Corporate Governance Expert

TL;DR: Disclosure procedural and compliant; no governance or material changes disclosed.

The report follows standard Section 2.02 and Item 9.01 practice by furnishing a press release and identifying exhibits. There are no disclosures of officer changes, material transactions, legal matters, or amendments to governance documents in this filing. The document’s statement that the information is furnished rather than filed is a common legal designation and does not indicate substantive governance actions within this report.

0001637715false00016377152025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

OnKure Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40315	47-2309515
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6707 Winchester Circle, #400
Boulder, Colorado				80301
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 307-2892

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		OKUR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended June 30, 2025.

The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) of this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release titled "OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update" dated August 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ONKURE THERAPEUTICS, INC.
Date:	August 12, 2025	By:	/s/ Jason Leverone
			Name: Jason Leverone Title: Chief Financial Officer

FAQ

What did OnKure (OKUR) disclose in this 8-K filing?

OnKure issued a press release reporting financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in the 8-K considered filed under the Exchange Act?

No. The filing explicitly states the information (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to Section 18 liabilities.

Where is OnKure's stock listed and what is the ticker symbol?

OnKure’s Class A common stock trades on The Nasdaq Stock Market under the symbol OKUR.

Does this 8-K include the company’s financial statements or numeric results?

No. The 8-K indicates a press release reporting quarterly financial results is attached, but the filing itself does not present specific financial figures.

Does the filing report any material transactions or officer changes?

No. The filing does not disclose any material transactions, executive departures, or governance changes.